|
Stories from the dialysis comunity across the globe.
|
|
BMI Doesn't Affect Kidney Transplant Survival - Renal and Urology News - Renal and Urology News |
 |
 |
July 22, 2015
No difference between defined BMI bands in patient or graft survival for transplanted patients.
(HealthDay News) -- For patients undergoing kidney transplantation, survival is unaffected by body mass index (BMI), according to a study published online in the American Journal of Transplantation.
Nithya Krishnan, M.B.B.S., from the University Hospitals Coventry and Warwickshire NHS Trust in the United Kingdom, and colleagues examined the impact of BMI on mortality in transplanted patients and those remaining on the waiting list in the United Kingdom. Data were analyzed from the U.K. Renal Registry and the National Health Service Blood and Transplant Organ Donation and Transplantation. From Jan. 1, 2004, to Dec. 31, 2010, 17,681 patients were listed, and BMI was recorded for 77%. Patients were followed through Dec. 31, 2011.
The researchers found that in all BMI bands, 1- and 5-year patient survival was significantly better in the transplant group versus the waiting list group. The results were essentially the same in analyses excluding live donor transplants. There was no cutoff observed among patients with higher BMI where there would be no benefit of transplantation in analyses of survival with BMI as a continuous variable. There was no difference in patient or graft survival between the defined BMI bands for the 8,088 transplanted patients.
"As BMI in the population is rising and likely to continue to rise, it is important that Renal Units respond to this challenge with positive attitude toward widening access to transplant," the authors write.
Sources
- Krishnan, N; Higgins, R; Short, A; et al. American Journal of Transplantation; doi: 10.1111/ajt.13363.
- Kalantar-Zadeh, K; von Visger, J; Foster, E; et al. American Journal of Transplantation; doi: 10.1111/ajt.13367.
|
|
|
A day of pampering for dialysis patients - ABC Local |
|
|
|
"I'm 51 but I still look young," Carole Reid said, a dialysis patient from Warburton, West Australia.
"I feel it inside, I'm young."
In the process of getting her hair dyed brown, Ms Reid was speaking from Salon Day at the Purple House, headquarters of Western Desert Dialysis in Alice Springs.
The organisation provides dialysis services and incorporates a range of other services around social support and well being.
The Salon Day is an annual event that gives patients the opportunity to get their hair dyed and enjoy a cook-up of damper.
Click on the audio to hear Carole Reid and Jedda Marshall (from Papunya) speaking to ABC Alice Springs' Alice Moldovan.
|
|
FINCHANNEL.com - “Cell therapy using human iPSC-derived renal progenitors ... - The FINANCIAL |
|
|
|
Summary:
New method for generating renal progenitors from human induced pluripotent stem cells (hiPSCs) was established;
Transplantation of human iPSC-derived renal progenitors ameliorated acute kidney injury (AKI) in mice;
Cell therapy using the hiPSC-derived renal progenitor cells could be developed for kidney diseases;
The research group found that transplantation of human iPSC-derived renal progenitors suppressed the renal dysfunction and histopathological changes associated with AKI in mice.
AKI is defined as a rapid loss of renal function resulting from various etiologies, with a mortality rate exceeding 60% among intensive care patients. Because conventional treatments have failed to alleviate this condition, a new innovative treatment option such as regenerative therapies is strongly anticipated. In this February, Italian research group reported that transplantation of human iPSC-derived renal progenitors via the tail vein ameliorated renal injury in a cisplatin-induced AKI mouse model, according to Astellas.
Transcription factors, Osr1 and Six2 interact synergistically to maintain nephron progenitor status during kidney organogenesis, and the combination of Osr1 and Six2 can be used as a specific marker set to define nephron progenitors. The research group has established a novel protocol to efficiently differentiate hiPSCs into OSR1+SIX2+ renal progenitors, and demonstrated the progenitors were able to form proximal renal tubule-like structures in vitro and in vivo. Moreover, in ischemia/reperfusion-induced AKI mouse model, renal subcapsular transplantation of these cells significantly suppressed the elevation of blood urea nitrogen and serum creatinine levels and attenuated histopathological changes, such as tubular necrosis.
This is the first report to demonstrate that the transplantation of renal progenitor cells differentiated from human iPSCs have therapeutic efficacy in the AKI mouse model induced by ischemia/reperfusion. No engraftment of transplanted renal progenitor cell indicates that trophic factors secreted from the cells exerted reno-protective effects on the host kidney.
These findings therefore suggest that cell therapy using hiPSC-derived renal progenitors might become one of therapeutic options for AKI patients by ameliorating renal tissue damage and possibly preventing transition to chronic tissue damage. Based on the findings, Astellas and CiRA will explore the possibility to develop new cell-based therapies for not only AKI but also chronic kidney disease (CKD).
|
|
|
Team reports success using iPS-derived cells to curb renal failure in mice - The Japan Times |
|
|
|
A group of researchers has succeeded in containing the symptoms of acute renal failure in mice by transplanting renal precursor cells made from human induced pluripotent stem cells, or iPSCs, into the animals.
The achievement by the team of scientists, including from Kyoto University’s Center for iPS Cell Research and Application, or CiRA, and Astellas Pharma Inc., found this method could also be effective in easing acute renal failure in human patients, according to findings published Tuesday in the online edition of U.S. science journal Stem Cells Translational Medicine on Tuesday.
In acute renal failure, kidney function deteriorates rapidly over several hours to several days due to a lack of blood or side effects of drugs. In Japan, about 5 percent of inpatients develop acute renal failure, and more than half of them die. Even survivors’ kidneys can be seriously damaged, and the disease can become chronic.
The group, including Kenji Osafune, professor at CiRA, developed a method to stably produce, from human iPS cells, renal precursor cells that only embryos have.
After the precursor cells were transplanted into mice, the team confirmed a decline in the levels of serum creatinine, a substance that increases in volume when kidney functions deteriorate. Necrosis and fibrosis of kidney cells in the mice were also contained, according to the team.
Osafune said that nutritional factors secreted from the transplanted human renal precursor cells helped ease the symptoms. This therapy could be effective also in the treatment of chronic kidney disease patients, totaling more than 13 million in Japan, he said.
|
|
Team reports success using iPS-derived cells to curb renal failure in mice ... - The Japan Times |
|
|
|
A group of researchers has succeeded in containing the symptoms of acute renal failure in mice by transplanting renal precursor cells made from human induced pluripotent stem cells, or iPSCs, into the animals.
The achievement by the team of scientists, including from Kyoto University’s Center for iPS Cell Research and Application, or CiRA, and Astellas Pharma Inc., found this method could also be effective in easing acute renal failure in human patients, according to findings published Tuesday in the online edition of U.S. science journal Stem Cells Translational Medicine on Tuesday.
In acute renal failure, kidney function deteriorates rapidly over several hours to several days due to a lack of blood or side effects of drugs. In Japan, about 5 percent of inpatients develop acute renal failure, and more than half of them die. Even survivors’ kidneys can be seriously damaged, and the disease can become chronic.
The group, including Kenji Osafune, professor at CiRA, developed a method to stably produce, from human iPS cells, renal precursor cells that only embryos have.
After the precursor cells were transplanted into mice, the team confirmed a decline in the levels of serum creatinine, a substance that increases in volume when kidney functions deteriorate. Necrosis and fibrosis of kidney cells in the mice were also contained, according to the team.
Osafune said that nutritional factors secreted from the transplanted human renal precursor cells helped ease the symptoms. This therapy could be effective also in the treatment of chronic kidney disease patients, totaling more than 13 million in Japan, he said.
|
|
|
|
|
<< Start < Prev 71 72 73 74 75 76 77 78 79 80 Next > End >>
|
|
Page 77 of 4210 |
Log in to explore the world's most comprehensive database of dialysis centres for free! 
Professional dialysis recruitment
